Public Offering Pricing, Market Activity, Upcoming Conferences, Drug Approvals, and Senior-Level Appointments - Research Reports on EPR, Medivation, Agilent, Caterpillar and UTC

NEW YORK, September 23, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding EPR Properties (NYSE: EPR), Medivation, Inc. (NASDAQ: MDVN), Agilent Technologies Inc. (NYSE: A), Caterpillar Inc. (NYSE: CAT) and United Technologies Corporation (NYSE: UTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6672-100free.

--
EPR Properties Research Reports
On September 18, 2014, EPR Properties (EPR) announced pricing of its underwritten public offering of 3.2 million of its common shares of beneficial interest at a price of $52.25 per share. The Company also granted the underwriters a 30-day option to purchase up to an additional 0.48 million common shares. EPR will receive c. $160.2 million in net proceeds, after deducting underwriting discounts and estimated offering expenses, and intends to use the proceeds to reduce the outstanding principal balance of its unsecured revolving credit facility. The Company expects the offering to close by September 23, 2014, subject to customary closing conditions. The full research reports on EPR are available to download free of charge at:

http://www.analystsreview.com/Sep-23-2014/EPR/report.pdf

--
Medivation, Inc. Research Reports
On September 10, 2014, Medivation, Inc. (Medivation) and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). According to Medivation, this new approved use follows a priority review of the supplemental New Drug Application (sNDA) that was based on results of the Phase III PREVAIL trial. Medivation's stock has gained over 4% since then, and is trading at all-time highs. On September 18, 2014, the stock closed at $100.93. The full research reports on Medivation are available to download free of charge at:

http://www.analystsreview.com/Sep-23-2014/MDVN/report.pdf

--
Agilent Technologies Inc. Research Reports
On September 17, 2014, Agilent Technologies Inc. (Agilent) announced that Mike McMullen, Senior Vice President, Agilent, and President of the Company's Chemical Analysis Group (CAG), will replace William Sullivan as the CEO on March 18, 2015. Sullivan will remain as an advisor through the end of the Company's fiscal year, October 31, 2015, when he will retire. To ensure smooth transition, Agilent's Board of Directors has appointed McMullen as President and Chief Operating Officer, with immediate effect. "This transition is the culmination of our succession planning, and comes at a time of strength as Agilent begins to deliver the shareholder benefits of the recent spinoff of its electronic measurement business," said James Cullen, Chairman of Agilent's Board of Directors. The full research reports on Agilent are available to download free of charge at:

http://www.analystsreview.com/Sep-23-2014/A/report.pdf

--
Caterpillar Inc. Research Reports
On September 18, 2014, Caterpillar Inc. (Caterpillar) announced that the Company will participate at the Citi 2014 Industrials Conference on September 23, 2014. Mike DeWalt, Vice President, Strategic Services and Rich Moore, Director of Investor Relations will participate at the event to represent Caterpillar, at 2:45 p.m. ET. The full research reports on Caterpillar are available to download free of charge at:

http://www.analystsreview.com/Sep-23-2014/CAT/report.pdf

--
United Technologies Corporation Research Reports
On September 18, 2014, United Technologies Corporation's (UTC) stock rose 0.45% from its previous day's close to end the trading session at $108.52. UTC's stock opened at day's low of $107.41 and touched an intraday high of $108.66. The stock has a 52-week low of $102.21 and a 52-week high of $120.66. Year-till-date, the stock has declined 4.64%, underperforming the NYSE Composite, which gained an upside of 6.00% during the same time period. The full research reports on UTC are available to download free of charge at:

http://www.analystsreview.com/Sep-23-2014/UTX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED